Due Diligence Assessment of CMC Activities
For planned acquisitions or licensing, a careful analysis of CMCl factors is vital to ensure no problem areas are overlooked.
Developing comprehensive chemistry, manufacturing, and controls programs are crucial to the success of a drug product. For planned acquisitions or licensing, a careful analysis of these critical factors is vital to ensure no problem areas are overlooked. Strategies for carrying out an effective due diligence exercise are described.
Read this article in Pharmaceutical Technology's Regulatory Sourcebook October 2020 eBook.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook
October 2020
Pages: 26–28
Citation
When referring to this article, please cite it as W. Lambert, “Due Diligence Assessment of CMC Activities," Pharmaceutical Technology Regulatory Sourcebook eBook (October 2020).
FDA Approves Novartis Oral Treatment for Adults with C3 Glomerulopathy
March 25th 2025Fabhalta (iptacopan) received a positive opinion for treatment of C3G from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has been approved twice before by FDA.
